Management of Gastrointestinal Stromal Tumour

Current Practices and Visions for the Future

Jean Yves Blay, Paolo G. Casali, Angelo Paolo Dei Tos, Axel Le Cesne, Peter Reichardt

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Gastrointestinal stromal tumour (GIST), while relatively rare, is the most common mesenchymal tumour of the gastrointestinal tract. These tumours are largely resistant to cytotoxic chemotherapy and, in the past, were typically managed surgically. However, as a result of the identification of activating mutations in the proto-oncogene KIT and the development of compounds that inhibit the KIT receptor tyrosine kinase, GISTs have, in the last 14 years, become the archetype of a targeted agent-responsive tumour. Due to the almost continual emergence of new data from clinical trials and other studies on GIST diagnosis and treatment, the management of this disease requires regular review. The 2013 ArcheoloGIST summit was convened in Prague, Czech Republic. Interaction between attending physicians and the expert faculty was a core component of the summit. The current article is based on discussions held during two interactive sessions at ArcheoloGIST 2013 in which the authors aimed to: (1) reach a consensus on the current management of GIST and (2) provide a vision for the future diagnosis and treatment of this disease.

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalOncology
Volume89
Issue number1
DOIs
Publication statusPublished - Jul 22 2015

Fingerprint

Gastrointestinal Stromal Tumors
Neoplasms
Proto-Oncogenes
Czech Republic
Receptor Protein-Tyrosine Kinases
Disease Management
Gastrointestinal Tract
Consensus
Clinical Trials
Physicians
Drug Therapy
Mutation
Therapeutics

Keywords

  • Adjuvant treatment
  • Diagnosis
  • Gastrointestinal stromal tumour
  • Management
  • Molecular profiling
  • Mutations
  • Relapse
  • Resistance
  • Risk assessment
  • Targeted agents

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Management of Gastrointestinal Stromal Tumour : Current Practices and Visions for the Future. / Blay, Jean Yves; Casali, Paolo G.; Dei Tos, Angelo Paolo; Le Cesne, Axel; Reichardt, Peter.

In: Oncology, Vol. 89, No. 1, 22.07.2015, p. 1-13.

Research output: Contribution to journalArticle

Blay, Jean Yves ; Casali, Paolo G. ; Dei Tos, Angelo Paolo ; Le Cesne, Axel ; Reichardt, Peter. / Management of Gastrointestinal Stromal Tumour : Current Practices and Visions for the Future. In: Oncology. 2015 ; Vol. 89, No. 1. pp. 1-13.
@article{61c7b57a68504620bbe6c28030d8f436,
title = "Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future",
abstract = "Gastrointestinal stromal tumour (GIST), while relatively rare, is the most common mesenchymal tumour of the gastrointestinal tract. These tumours are largely resistant to cytotoxic chemotherapy and, in the past, were typically managed surgically. However, as a result of the identification of activating mutations in the proto-oncogene KIT and the development of compounds that inhibit the KIT receptor tyrosine kinase, GISTs have, in the last 14 years, become the archetype of a targeted agent-responsive tumour. Due to the almost continual emergence of new data from clinical trials and other studies on GIST diagnosis and treatment, the management of this disease requires regular review. The 2013 ArcheoloGIST summit was convened in Prague, Czech Republic. Interaction between attending physicians and the expert faculty was a core component of the summit. The current article is based on discussions held during two interactive sessions at ArcheoloGIST 2013 in which the authors aimed to: (1) reach a consensus on the current management of GIST and (2) provide a vision for the future diagnosis and treatment of this disease.",
keywords = "Adjuvant treatment, Diagnosis, Gastrointestinal stromal tumour, Management, Molecular profiling, Mutations, Relapse, Resistance, Risk assessment, Targeted agents",
author = "Blay, {Jean Yves} and Casali, {Paolo G.} and {Dei Tos}, {Angelo Paolo} and {Le Cesne}, Axel and Peter Reichardt",
year = "2015",
month = "7",
day = "22",
doi = "10.1159/000374120",
language = "English",
volume = "89",
pages = "1--13",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Management of Gastrointestinal Stromal Tumour

T2 - Current Practices and Visions for the Future

AU - Blay, Jean Yves

AU - Casali, Paolo G.

AU - Dei Tos, Angelo Paolo

AU - Le Cesne, Axel

AU - Reichardt, Peter

PY - 2015/7/22

Y1 - 2015/7/22

N2 - Gastrointestinal stromal tumour (GIST), while relatively rare, is the most common mesenchymal tumour of the gastrointestinal tract. These tumours are largely resistant to cytotoxic chemotherapy and, in the past, were typically managed surgically. However, as a result of the identification of activating mutations in the proto-oncogene KIT and the development of compounds that inhibit the KIT receptor tyrosine kinase, GISTs have, in the last 14 years, become the archetype of a targeted agent-responsive tumour. Due to the almost continual emergence of new data from clinical trials and other studies on GIST diagnosis and treatment, the management of this disease requires regular review. The 2013 ArcheoloGIST summit was convened in Prague, Czech Republic. Interaction between attending physicians and the expert faculty was a core component of the summit. The current article is based on discussions held during two interactive sessions at ArcheoloGIST 2013 in which the authors aimed to: (1) reach a consensus on the current management of GIST and (2) provide a vision for the future diagnosis and treatment of this disease.

AB - Gastrointestinal stromal tumour (GIST), while relatively rare, is the most common mesenchymal tumour of the gastrointestinal tract. These tumours are largely resistant to cytotoxic chemotherapy and, in the past, were typically managed surgically. However, as a result of the identification of activating mutations in the proto-oncogene KIT and the development of compounds that inhibit the KIT receptor tyrosine kinase, GISTs have, in the last 14 years, become the archetype of a targeted agent-responsive tumour. Due to the almost continual emergence of new data from clinical trials and other studies on GIST diagnosis and treatment, the management of this disease requires regular review. The 2013 ArcheoloGIST summit was convened in Prague, Czech Republic. Interaction between attending physicians and the expert faculty was a core component of the summit. The current article is based on discussions held during two interactive sessions at ArcheoloGIST 2013 in which the authors aimed to: (1) reach a consensus on the current management of GIST and (2) provide a vision for the future diagnosis and treatment of this disease.

KW - Adjuvant treatment

KW - Diagnosis

KW - Gastrointestinal stromal tumour

KW - Management

KW - Molecular profiling

KW - Mutations

KW - Relapse

KW - Resistance

KW - Risk assessment

KW - Targeted agents

UR - http://www.scopus.com/inward/record.url?scp=84937515111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937515111&partnerID=8YFLogxK

U2 - 10.1159/000374120

DO - 10.1159/000374120

M3 - Article

VL - 89

SP - 1

EP - 13

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -